

Mycobacterium tuberculosis specific antigen-stimulated CD27-CD38+IFN- γ +CD4+ T cells for active tuberculosis diagnosis

Bo Su (✉ su_bo_s@hotmail.com)

Shanghai Pulmonary Hospital

Yong fang

Tongji University

Na Wang

Shanghai Pulmonary Hospital

Liang Tang

Shanghai Pulmonary Hospital

Xiaojun Yang

Shanghai Pulmonary Hospital

Yuan Tang

Shanghai Pulmonary Hospital

Lin Li

Shanghai Pulmonary Hospital

Wenfei Wu

Shanghai Pulmonary Hospital

Wei Sha

Tongji University

Research Article

Keywords: tuberculosis, diagnosis, biomarker, flow cytometry, CD27, CD38, IFN- γ

Posted Date: March 29th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1448711/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Traditional bacteriological tests are time-consuming and of low sensitivity for the diagnosis of active tuberculosis (ATB). The purpose of this study is to investigate the accuracy of CD27⁺CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ for active tuberculosis (ATB) diagnosis.

Methods: This prospective diagnostic accuracy study was conducted at Shanghai Pulmonary Hospital between January 2019 and December 2021. Patients with ATB, non-tuberculosis mycobacterium infection (NTM), latent tuberculosis infection (LTBI), other respiratory diseases (OD), and healthy individuals (HC) were enrolled. The accuracy of CD27⁺CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ and other phenotypic markers for ATB diagnosis was assessed.

Results: A total of 376 patients (237 ATB, 38 LTBI, 8 NTM, 50 OD, and 43 HC) were enrolled. The ratios of CD4⁺IFN- γ ⁺CD27⁺ and CD4⁺IFN- γ ⁺CD27⁻CD38⁺ profiles in CD4⁺IFN- γ ⁺ cells and the ratios of CD4⁺IFN- γ ⁺CD38⁺, CD4⁺IFN- γ ⁺CD27⁺, and CD4⁺IFN- γ ⁺CD38⁺CD27⁻ profiles in CD4⁺ cells in the ATB group were significantly higher than in the other groups. The area under the curve (AUC) of CD27⁺CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ for the diagnosis of ATB was the highest, with a value of 0.890. With the optimal cutoff value of 1.34×10^{-4} , the sensitivity and specificity of CD27⁺CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ for ATB diagnosis was 0.869 and 0.849, respectively.

Conclusion: CD27⁺CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ might be an effective biomarker for active tuberculosis diagnosis.

Introduction

Tuberculosis (TB) is the ninth leading cause of death in the world, ahead of HIV/AIDS [1]. Despite great advances in therapy, the world still faces a huge burden of TB. There are about 2 billion people infected with *Mycobacterium tuberculosis* (MTB) worldwide [1, 2], and China is one of the 30 countries with the highest burden of TB and latent TB infection (LTBI) identified by the World Health Organization (WHO) [3]. It was recently estimated that China had the highest LTBI burden in the world, with approximately 350 million persons living with the infection [4, 5].

The rapid and accurate diagnosis of MTB infection is a critical problem in preventing and controlling TB and determining treatment efficacy. Conventional diagnostic methods are time-consuming (e.g., TB culture) or have low specificity (e.g., the tuberculin skin test [TST]) [6]. In addition, some methods cannot distinguish active TB (ATB) from LTBI (e.g., interferon- γ release assays [IGRAs]) [7]. It is challenging to differentiate ATB from LTBI and other respiratory diseases, and misdiagnosis often occurs [8, 9]. Extra-pulmonary TB (EPTB) accounts for a large proportion of TB [10, 11]. Since the results of etiology and pathology are difficult to obtain for tuberculous serous effusion (such as tuberculous pleuritis, tuberculous peritonitis, tuberculous pericarditis, tuberculous meningitis, etc.), the means of diagnosis and differential diagnosis are limited.

The cellular immune response mediated by T lymphocytes plays a key role in TB infection and pathogenesis [12, 13]. The surface molecules of the T cells are the molecular basis for the mutual recognition and interaction between T cells and other cells and molecules [14, 15]. CD27 is a costimulatory receptor expressed on the surface of CD4⁺ T cells [16]. Early-differentiated CD27⁺ memory CD4 T cells are thought to recirculate primarily in secondary lymphoid organs, while late-differentiated CD27⁻ memory T cells exhibit additional effector functions [17] and preferentially migrate to peripheral sites of inflammation, such as the lungs during ATB [18]. CD38 is a transmembrane glycoprotein expressed on many types of immune cells. It can catalyze the degradation of nicotinamide adenine dinucleotide (NAD) and its precursors that are necessary for bacterial growth [19, 20]. A study showed that CD38 inhibits the metabolism of pathogens by degrading NAD and its precursors in activated immune cells, thus limiting the development or progression of infection [21].

Recent studies showed that compared with LTBI, CD27⁻ and CD38⁺ are mainly expressed in ATB and could be used as markers to distinguish the two diseases [22–24], but there are few studies on the combined CD27⁻ and CD38⁺ profile. Therefore, this study aimed to detect the co-expression of CD27 and CD38 molecules in CD4⁺ and CD4⁺IFN- γ ⁺ T cells and investigate the accuracy of CD27⁺CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ and other MTB-specific phenotypic markers for ATB diagnosis.

Methods

Study design and population

This prospective diagnostic study was conducted in Shanghai Pulmonary Hospital, School of Medicine of Tongji University, between January 2019 and December 2021. The inclusion criteria were 1) aged 14-70 years, 2) healthy volunteers (HC) or patients with ATB, LTBI, non-tuberculosis mycobacterium infection (NTM), or other respiratory diseases (OD). The exclusion criteria were 1) primary or secondary immunodeficiency, including HIV, long-term steroid use, or co-existing autoimmune diseases, 2) diabetes or viral hepatitis, 3) history of anti-tuberculosis treatments. This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Shanghai Pulmonary Hospital. All participants signed the informed consent forms.

ATB (including active pulmonary TB (PTB) and active EPTB) was diagnosed according to i) no previous history of TB, ii) positive sputum, bronchoalveolar lavage fluid (BALF), or bacteriological tests, including positive acid-fast staining, positive MTB culture (Bectec960), or positive Gene-XPERT test, and iii) no other lung diseases [25-28]. LTBI was defined as household contacts of newly diagnosed TB patients with positive IGRA, with no evidence of clinically manifest active TB[29]. OD was defined as patients with any other respiratory diseases except TB, and with negative IGRA results. Healthy volunteers were those had negative IGRA results and no history of TB exposure. Sputum smear-positive patients with negative sputum MTB culture results were diagnosed as non-tuberculous mycobacteria (NTM).

Data collection

Demographic information including gender and age of all participants was recorded. For each participant, 0.5 ml whole blood was collected in heparin anticoagulant tubes. Acid fast and Gene-XPERT were used for ATB screening. The results of MTB culture and IGRA were recorded.

ESAT6/CFP10 stimulation and flow cytometry

Within 4 h of blood collection, the whole blood was added into sample tubes containing 10µg/mL ESAT6/CFP10 polypeptide antigen (Beckman Coulter, Brea, CA, USA). Brefeldin A (10µg/mL, Biolegend, San Diego, CA, USA) was added as a Golgi transport inhibitor, and the whole blood was incubated at 37°C with 5% CO₂ for 16 h. After culture, 2.5 mL of erythrocyte lysis solution and fixative solution (3% diethylene glycol, 2% formaldehyde, and 0.75% methanol) were added and incubated at room temperature for 10 min. The cells were centrifuged at 600 ×g for 5 min. The supernatant was discarded, and 375 µL Perfix-NC membrane breaking solution (Beckman Coulter) was added and mixed. IFN-γ-FITC was added. Then, 5µL of CD4-PE, CD3-ECD, CD27-PE-CY5.5, and CD38-PE-CY7 were mixed and incubated for 45 min in the dark. Phosphate-buffered saline (PBS, 3 mL) was added. The cells were centrifuged at 600 ×g for 5 min, and the supernatant was discarded. After adding 300µL PBS, a Beckman Coulter DxFLEX flow cytometer was used for rapid collection (60µL/min). The collection stop condition was set to 100,000 CD4⁺ cells or 300 s of whole blood. FlowJo V10 (Treestar, Ashland, OR) was used for data analysis. The ratio of CD4⁺IFN-γ⁺CD38⁺/CD4⁺IFN-γ⁺, CD4⁺IFN-γ⁺CD27⁺/CD4⁺IFN-γ⁺, CD4⁺IFN-γ⁺CD38⁺CD27⁺/CD4⁺IFN-γ⁺, CD4⁺IFN-γ⁺CD38⁺CD27⁺/CD4⁺, CD4⁺IFN-γ⁺CD38⁺/CD4⁺, CD4⁺IFN-γ⁺CD27⁺/CD4⁺ was measured.

Statistical analysis

Statistical analyses were performed using SPSS 18 (SPSS, Armonk, NY, USA) and Graph Pad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). Continuous variables are described as means±standard deviation (SD), and categorical variables as n (%). The Kruskal-Wallis test was used for comparison of independent samples between multiple groups, Dunn's test was used for pairwise comparison between multiple groups, and the Mann-Whitney U-test was used for comparison of independent samples between two groups. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic performance of each biomarker. The areas under the curves (AUCs) were compared by the DeLong test. The optimal cutoff value of variables was identified according to the maximum Youden index. Two-sided P-values <0.05 were considered statistically significant.

Results

A total of 376 participants, including 216 males and 160 females with an average age of 41.2±16.9 years were enrolled (Table 1). There were 237 cases of ATB (177 cases of PTB and 60 cases of EPTB), 38 cases of LTBI, 8 cases of NTM, 50 cases with OD, and 43 HC (Fig. 1).

Table 1
Characteristics of the participants

	ATB (n = 237)	LTBI (n = 38)	NTM (n = 8)	OD (n = 50)	HC (n = 43)	P
Male (n, %)	155 (65.4%)	15 (39.5%)	5 (62.5%)	25 (50.0%)	16 (37.2%)	P < 0.001
Age (year)	38.0±16.4	44.6±13.9	48.8±11.0	56.3±16.5	36.5±12.8	P < 0.001
EPTB (n, %)	60 (25.3%)	/	/	/	/	
TB culture						
N/A (n, %)	0	0	5 (62.5%)	3 (6.0%)	0	
Negative (n, %)	48(20.3%)	38 (100%)	3 (37.5%)	47 (94.0%)	43 (100%)	
Positive (n, %)	189(79.7%)	0	0	0	0	
IGRA						
N/A (n, %)	21 (8.9%)	0	1 (12.5%)	3 (6.0%)	0	
Indeterminate (n, %)	1 (0.4%)	0	0	0	0	
Negative (n, %)	10 (4.2%)	0	4 (50.0%)	47 (94.0%)	43 (100%)	
Positive (n, %)	205 (86.5%)	38 (100%)	3 (37.5%)	0	0	
ATB: active tuberculosis; EPTB: extrapulmonary tuberculosis; LTBI: latent tuberculosis infection; NTM: non-tuberculous mycobacterium pulmonary disease; HC: healthy control; OD: other respiratory diseases; N/A: not available.						

The CD27 or CD38 expression in ESAT-6/CFP-10 peptides stimulated CD4⁺IFN- γ ⁺ T cells was compared with the unstimulated cells (Fig. 2). The rates of CD27⁻, CD38⁺, and CD27⁻CD38⁺ were significantly higher in the ATB group than in the non-ATB groups (all P < 0.001) (Fig. 3A-C). This also indicates that CD27, CD38⁺, and CD27⁻CD38⁺ are mainly found in the CD4⁺IFN- γ ⁺ T cells of ATB patients. The ratio of CD4⁺IFN- γ ⁺CD27⁻ and CD4⁺IFN- γ ⁺CD38⁺CD27⁻ profiles in CD4⁺IFN- γ ⁺ cells stimulated by ESAT 6/CFP10 in the ATB group were higher than that in LTBI (P = 0.02 and P < 0.001, respectively), NTM (P = 0.001 and P < 0.001, respectively), OD (both P < 0.001), and HC groups (both P < 0.001) (Fig. 3D, 3F). The ratio of CD4⁺IFN- γ ⁺CD38⁺ profile in CD4⁺IFN- γ ⁺ cells of the ATB group was higher than the LTBI (P = 0.01) and OD groups (all P < 0.001), but no difference was found between the ATB and the NTM or HC group (Fig. 3E). The rates of CD4⁺IFN- γ ⁺CD38⁺, CD4⁺IFN- γ ⁺CD27⁻, and CD4⁺IFN- γ ⁺CD38⁺CD27⁻ profiles in CD4⁺ T cell subsets in the ATB group were significantly higher than in the other groups (all P < 0.001) (Fig. 3G-I).

The diagnostic values (including sensitivity, specificity, negative predictive value, positive predictive value, positive likelihood ratio, negative likelihood ratio, and accuracy) of CD4⁺IFN- γ ⁺CD38⁺/CD4⁺IFN- γ ⁺, CD4⁺IFN- γ ⁺CD27⁻/CD4⁺IFN- γ ⁺, CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺IFN- γ ⁺, CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺, CD4⁺IFN- γ ⁺CD38⁺/CD4⁺, CD4⁺IFN- γ ⁺CD27⁻/CD4⁺ for the diagnosis and differential diagnosis of TB were evaluated (Table 2). CD4⁺IFN- γ ⁺CD38⁺/CD4⁺IFN- γ ⁺ had the highest sensitivity (0.899) and CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ had the highest specificity (0.849). ROC curves for ATB diagnosis were performed and the AUCs of the six markers were greater than 0.7 except CD4⁺IFN- γ ⁺CD38⁺/CD4⁺ IFN- γ ⁺ (Fig. 4A). The AUC of CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺, which was 0.890, was the highest compared with the other markers (Delong test, P < 0.05), indicating that the CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ had the highest value in the diagnosis and differential diagnosis of ATB. At the cutoff value, the sensitivity and specificity of CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ were both above 80% (Fig. 4B). At the cutoff value of $1.34 \cdot 10^{-4}$, CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ exhibited good differential diagnosis ability for ATB, as most ATB cases had CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ values over $1.34 \cdot 10^{-4}$ and most non-ATB cases had values below $1.34 \cdot 10^{-4}$ (Fig. 4C). The sensitivity, specificity, and accuracy of CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ were 0.869, 0.849, and 0.862, respectively. The positive predictive value was 0.907, and the negative predictive value was 0.792.

Table 2
Diagnostic performance of different phenotypic markers

	Cutoff	Se	Sp	PPV	NPV	FPR	FNR	+LR	-LR	Accuracy	Youden
CD4 ⁺ IFN γ ⁺ CD27 ⁻ CD38 ⁺ /CD4 ⁺	1.34·10 ⁻⁴	0.869	0.849	0.907	0.792	0.151	0.130	5.753	0.154	0.862	0.718
CD4 ⁺ IFN γ ⁺ CD27 ⁻ /CD4 ⁺	2.11·10 ⁻⁴	0.781	0.849	0.898	0.694	0.151	0.219	5.167	0.258	0.806	0.630
CD4 ⁺ IFN γ ⁺ CD38 ⁺ /CD4 ⁺	2.56·10 ⁻⁴	0.776	0.791	0.864	0.675	0.209	0.224	3.721	0.283	0.782	0.568
CD4 ⁺ IFN γ ⁺ CD27 ⁻ CD38 ⁺ /CD4 ⁺ IFN γ ⁺	1.91·10 ⁻¹	0.793	0.705	0.821	0.667	0.295	0.207	2.689	0.293	0.761	0.498
CD4 ⁺ IFN γ ⁺ CD27 ⁻ /CD4 ⁺ IFN γ ⁺	3.21·10 ⁻¹	0.624	0.777	0.827	0.548	0.223	0.376	2.800	0.483	0.681	0.401
CD4 ⁺ IFN γ ⁺ CD38 ⁺ /CD4 ⁺ IFN γ ⁺	1.80·10 ⁻¹	0.899	0.417	0.724	0.707	0.583	0.101	1.542	0.243	0.721	0.316

Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; FPR: false positive rate; FNR: false-negative rate; +LR: positive likelihood ratio; -LR: negative likelihood ratio.

In addition, we investigated the difference in the rates of CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ between TB culture-negative (culture⁻) and TB culture-positive (culture⁺) ATB patients. Among the 237 ATB cases, 189 cases were TB culture⁺, and 48 were TB culture⁻. The rates of CD4⁺IFN- γ ⁺CD38⁺CD27⁻ in CD4⁺ T cells stimulated by ESAT 6/CFP10 showed no significant difference between TB culture⁺ and TB culture⁻ (P > 0.05). Compared with the other groups, the rates of CD4⁺IFN- γ ⁺CD38⁺CD27⁻ in the TB culture⁻ group were higher than in the LTBI (P < 0.001), NTM (P = 0.003), OD (P < 0.001), and HC groups (P < 0.001) (Fig. 5A). The rates of CD4⁺IFN- γ ⁺CD38⁺CD27⁻ on CD4⁺ cells of PTB and EPTB were also compared (Fig. 5B). There were 177 cases of PTB and 60 cases of EPTB among the 237 ATB patients. The rates of CD4⁺IFN- γ ⁺CD38⁺CD27⁻ in CD4⁺ cells showed no significant difference between PTB and EPTB (P > 0.05). The rates of CD4⁺IFN- γ ⁺CD38⁺CD27⁻ in EPTB were higher than in the LTBI, NTM, OD, and HC groups (all P < 0.001). Therefore, CD4⁺IFN- γ ⁺CD38⁺CD27⁻ could also be used as a marker the diagnosis and differential diagnosis of ATB patients with TB culture⁻ and EPTB.

Discussion

The diagnostic performance of CD27⁻CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ and other MTB-specific phenotypic markers for ATB diagnosis was evaluated in this study. The AUC of CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ for the diagnosis of ATB was the highest (0.890), and the sensitivity and specificity was 0.869 and 0.849 with the optimal cutoff value of CD4⁺IFN- γ ⁺CD38⁺CD27⁻/CD4⁺ as 1.34·10⁻⁴. Therefore, CD27⁻CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ might be an effective biomarker for ATB diagnosis and differential diagnosis in future clinical application.

In recent years, the research on T cell-related molecular markers has been a hot topic. Xu et al. [24] evaluated CD27 in CD27⁻IFN- γ ⁺CD4⁺ T cells for differential diagnosis in TB-unexposed healthy people, TB contacts, and smear-negative TB and concluded that the percentage of CD27⁻IFN- γ ⁺CD4⁺ cells can distinguish smear-negative TB patients from the other two groups (AUC = 0.88, sensitivity 82.1%, specificity 80.0%). The study focused on the differential diagnosis of sputum smear-negative ATB and LTBI, but many of the smear-negative patients were culture-positive. There are still some ATB patients with both negative smear and culture, and it is challenging to distinguish ATB from LTBI in these patients. Therefore, it is more meaningful to compare ATB with LTBI in sputum culture-negative, which is also one of the key contents of the present study. Latorre et al. [22] found that the rates of CD27⁻ and CCR4⁺ in IFN- γ ⁺ TNF- α ⁺CD4⁺ T cells stimulated by ESAT⁻6/CFP⁻10 or PPD had a high diagnostic value and a high diagnostic accuracy between ATB and LTBI, but the ATB and LTBI participants in the study were enrolled within the first 4 weeks of initiation of anti-TB therapy or prophylactic anti-TB therapy, and it is questionable whether anti-TB therapy interfered with the results. Silveira-mattos et al. [23] focused on CD38, HLADR, and Ki67. The results showed that the rates of CD38⁺, HLADR⁺, or Ki67⁺ in IFN- γ ⁺CD4⁺ T cells could differentiate LTBI from ATB. HLADR⁺ and Ki67⁺ could identify EPTB and PTB accurately. HIV infection did not affect the ability of these markers to distinguish between ATB and LTBI, EPTB, and PTB. Still, a large proportion of EPTB tends to be combined with PTB, so the comparison is worth considering.

This study focused on the rates of CD27⁻ and CD38⁺ and their co-occurrence. The results showed that after peripheral blood was stimulated by ESAT 6/CFP10, the rates of CD4⁺IFN- γ ⁺CD27⁻ and CD4⁺IFN- γ ⁺CD27⁻ on CD4⁺ IFN- γ ⁺ cells of ATB were higher than in the other groups. The rate of CD4⁺IFN- γ ⁺CD38⁺ in ATB was higher than in LTBI and OD, but there were no differences with NTM and HC groups. The rates of CD4⁺IFN- γ ⁺CD38⁺, CD4⁺IFN- γ ⁺CD27⁻, and CD4⁺IFN- γ ⁺CD27⁻CD38⁺ subsets in CD4⁺ cells were higher in ATB than in the other groups. Similar results were observed for

the rates of CD4⁺IFN- γ ⁺CD38⁺ and CD4⁺IFN- γ ⁺CD27⁻, consistent with the previous study mentioned above. Nevertheless, there are few studies on CD4⁺IFN- γ ⁺CD27⁻CD38⁺, and additional studies are necessary to strengthen the results. ROC curves were performed for the proportions of CD4⁺IFN- γ ⁺CD38⁺, CD4⁺IFN- γ ⁺CD27⁻, and CD4⁺IFN- γ ⁺CD27⁻CD38⁺ in CD4⁺ and CD4⁺IFN- γ ⁺ as diagnostic indexes. According to their AUC, CD4⁺IFN- γ ⁺CD27⁻/CD4⁺IFN- γ ⁺ and CD4⁺IFN- γ ⁺CD27⁻CD38⁺/CD4⁺IFN- γ ⁺ have diagnostic value for ATB. The AUC of CD4⁺IFN- γ ⁺CD27⁻CD38⁺/CD4⁺ was 0.890, indicating the highest diagnosis value. The reason that the diagnostic value of each biomarker on CD4⁺ cells is higher than CD4⁺IFN- γ ⁺ may be related to the both effect of CD27⁻CD38⁺ and IFN- γ , but the exact mechanisms remain to be explored in future research.

As it is difficult to diagnose culture-negative TB clinically, acid-fast sputum staining tests cannot distinguish TB from NTM. In countries and regions with relatively poor public health resources, the gene-XPRT test is not easily accessible. On the other hand, EPTB is more difficult to diagnose than PTB. The diagnosis is usually made by pathology, excluding other diseases and diagnostic treatment, which is expensive in time and resources. In this study, the results showed no difference of CD4⁺IFN- γ ⁺CD27⁻CD38⁺ on CD4⁺ neither between TB culture⁺ and TB culture⁻ nor between PTB and EPTB. Still, the rates were higher in TB culture⁻ and EPTB than in the LTBI, NTM, OD, and HC groups. Therefore, CD4⁺IFN- γ ⁺CD27⁻CD38⁺ cell subsets could be helpful for culture⁻ TB and EPTB diagnosis.

This study has certain limitations. The study aimed to explore the indicators for ATB diagnosis, and the phenotypic markers in the ATB group were compared with the LTBI, NTM, OD, and HC groups because the differential diagnosis of these groups is also of great clinical value. Unfortunately, the sample size for the NTM group was relatively small, mainly because it was a single-center study with a limited sample size. Therefore, multicenter studies with larger samples should be carried out. In addition, this study did not examine the effects of treatments on CD4⁺IFN- γ ⁺CD27⁻CD38⁺ cell subsets.

In conclusion, CD27⁻CD38⁺IFN- γ ⁺CD4⁺/CD4⁺ could be used as an effective biomarker for TB diagnosis and differential diagnosis.

Declarations

Ethics approval and consent to participate

This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Shanghai Pulmonary Hospital. And informed consent was obtained from All participants.

Consent for publication

All authors consent to publication if our article is accepted for publication by the journal.

Availability of data and material

All the data and materials presented in this study are included in the article.

Author contributions

Bo Su, Wei Sha and Yong Fang designed the study protocol. Yong Fang, Na Wang and Lin Li recruited subjects and collected peripheral blood samples. Liang Tang and Xiao-Jun Yang performed flow cytometry on peripheral blood samples. Yuan Tang analyzed flow cytometry data. Yong Fang and Na Wang collated data. Yong Fang and Bo Su prepared all the figures and Tables. Yong Fang wrote the main manuscript text. All authors reviewed the manuscript. Bo Su, Wei Sha and Wen-Fei Wu put forward suggestions for revision.

Funding

This work was funded by Shanghai Clinical Research Center for infectious disease (tuberculosis) (Grant ID :19MC1910800); by Shanghai key clinical specialty construction project - Tuberculosis department (Grant ID :Shslczdzc03001); by Clinical study on the diagnostic value and efficacy evaluation of peripheral blood flow cytometry for tuberculosis (Grant ID :fk18008)).

Competing interests

There were no conflicts of interest.

Acknowledgements

The authors sincerely thank all the study participants.

References

1. Collaborators GBDT. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. *Lancet Infect Dis.* 2018;18(3):261-84. Epub 2017/12/11. doi: 10.1016/S1473-3099(17)30703-X. PubMed PMID: 29223583; PubMed Central PMCID: PMC5831985.
2. Grobusch MP, Kapata N. Global burden of tuberculosis: where we are and what to do. *Lancet Infect Dis.* 2018;18(12):1291-3. Epub 2018/12/07. doi: 10.1016/S1473-3099(18)30654-6. PubMed PMID: 30507444.
3. WHO. Global tuberculosis report 2018. WHO/CDS/TB/. 2018;20.
4. Zhu S, Xia L, Yu S, Chen S, Zhang J. The burden and challenges of tuberculosis in China: findings from the Global Burden of Disease Study 2015. *Sci Rep.* 2017;7(1):14601. Epub 2017/11/04. doi: 10.1038/s41598-017-15024-1. PubMed PMID: 29097809; PubMed Central PMCID: PMC5668247.
5. Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. *Int J Infect Dis.* 2020;92S:S37-S40. Epub 2020/03/03. doi: 10.1016/j.ijid.2020.02.034. PubMed PMID: 32114201.
6. Galindo JL, Galeano AC, Suarez-Zamora DA, Callejas AM, Caicedo-Verastegui MP, Londono D, et al. Comparison of the QuantiFERON-TB and tuberculin skin test for detection of latent tuberculosis infection in cancer patients in a developing country. *ERJ Open Res.* 2019;5(4). Epub 2019/10/23. doi: 10.1183/23120541.00258-2018. PubMed PMID: 31637254; PubMed Central PMCID: PMC6791967. A.C. Galeano has nothing to disclose. Conflict of interest: D.A. Suarez-Zamora has nothing to disclose. Conflict of interest: A.M. Callejas has nothing to disclose. Conflict of interest: M.P. Caicedo-Verastegui has nothing to disclose. Conflict of interest: D. Londono has nothing to disclose. Conflict of interest: L.G. Garcia-Herreros has nothing to disclose. Conflict of interest: A.V. Ospina Serrano has nothing to disclose. Conflict of interest: A. Saavedra has nothing to disclose. Conflict of interest: P. Garcia-herreros has nothing to disclose. Conflict of interest: D.M. Palacios has nothing to disclose. Conflict of interest: A.M. Baldion has nothing to disclose.
7. Kwiatkowska S. The IGRA tests: where are we now? *Pneumonol Alergol Pol.* 2015;83(2):95-7. Epub 2015/03/11. doi: 10.5603/PiAP.2015.0015. PubMed PMID: 25754049.
8. Tang F, Lin LJ, Guo SL, Ye W, Zha XK, Cheng Y, et al. Key determinants of misdiagnosis of tracheobronchial tuberculosis among senile patients in contemporary clinical practice: A retrospective analysis. *World J Clin Cases.* 2021;9(25):7330-9. Epub 2021/10/08. doi: 10.12998/wjcc.v9.i25.7330. PubMed PMID: 34616799; PubMed Central PMCID: PMC8464447.
9. Nguyen-Ho L, Nguyen-Tiet A, Chang YS. Asthma and pulmonary tuberculosis: misdiagnosis or coexistence. *Respirol Case Rep.* 2021;9(7):e00797. Epub 2021/06/15. doi: 10.1002/rcr2.797. PubMed PMID: 34123385; PubMed Central PMCID: PMC8173453.
10. Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary Tuberculosis: Pathophysiology and Imaging Findings. *Radiographics.* 2019;39(7):2023-37. Epub 2019/11/08. doi: 10.1148/rg.2019190109. PubMed PMID: 31697616.
11. Cherian JJ, Lobo I, Sukhlecha A, Chawan U, Kshirsagar NA, Nair BL, et al. Treatment outcome of extrapulmonary tuberculosis under Revised National Tuberculosis Control Programme. *Indian J Tuberc.* 2017;64(2):104-8. Epub 2017/04/16. doi: 10.1016/j.ijtb.2016.11.028. PubMed PMID: 28410692.
12. de Martino M, Lodi L, Galli L, Chiappini E. Immune Response to Mycobacterium tuberculosis: A Narrative Review. *Front Pediatr.* 2019;7:350. Epub 2019/09/12. doi: 10.3389/fped.2019.00350. PubMed PMID: 31508399; PubMed Central PMCID: PMC6718705.
13. Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. *Cell Mol Immunol.* 2017;14(12):963-75. Epub 2017/09/12. doi: 10.1038/cmi.2017.88. PubMed PMID: 28890547; PubMed Central PMCID: PMC5719146.
14. Dinur-Schejter Y, Zaidman I, Mor-Shaked H, Stepensky P. The Clinical Aspect of Adaptor Molecules in T Cell Signaling: Lessons Learnt From Inborn Errors of Immunity. *Front Immunol.* 2021;12:701704. Epub 2021/08/31. doi: 10.3389/fimmu.2021.701704. PubMed PMID: 34456914; PubMed Central PMCID: PMC8397411.
15. Hwang JR, Byeon Y, Kim D, Park SG. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. *Exp Mol Med.* 2020;52(5):750-61. Epub 2020/05/23. doi: 10.1038/s12276-020-0435-8. PubMed PMID: 32439954; PubMed Central PMCID: PMC7272404.
16. Adekambi T, Ibegbu CC, Cagle S, Ray SM, Rengarajan J. High Frequencies of Caspase-3 Expressing Mycobacterium tuberculosis-Specific CD4(+) T Cells Are Associated With Active Tuberculosis. *Front Immunol.* 2018;9:1481. Epub 2018/07/10. doi: 10.3389/fimmu.2018.01481. PubMed PMID: 29983703; PubMed Central PMCID: PMC6026800.
17. Petruccioli E, Petrone L, Vanini V, Cuzzi G, Navarra A, Gualano G, et al. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. *J Infect.* 2015;71(5):526-33. Epub 2015/08/09. doi: 10.1016/j.jinf.2015.07.009. PubMed PMID: 26253021.
18. Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. *Eur J Immunol.* 2009;39(8):2076-82. Epub 2009/08/13. doi: 10.1002/eji.200939722. PubMed PMID: 19672903.
19. Aksoy P, Escande C, White TA, Thompson M, Soares S, Benech JC, et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. *Biochem Biophys Res Commun.* 2006;349(1):353-9. Epub 2006/08/29. doi: 10.1016/j.bbrc.2006.08.066. PubMed PMID: 16935261.
20. Aksoy P, White TA, Thompson M, Chini EN. Regulation of intracellular levels of NAD: a novel role for CD38. *Biochem Biophys Res Commun.* 2006;345(4):1386-92. Epub 2006/05/30. doi: 10.1016/j.bbrc.2006.05.042. PubMed PMID: 16730329.

21. Hogan KA, Chini CCS, Chini EN. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. *Front Immunol.* 2019;10:1187. Epub 2019/06/20. doi: 10.3389/fimmu.2019.01187. PubMed PMID: 31214171; PubMed Central PMCID: PMC655258.
22. Latorre I, Fernandez-Sanmartin MA, Muriel-Moreno B, Villar-Hernandez R, Vila S, Souza-Galvao ML, et al. Study of CD27 and CCR4 Markers on Specific CD4(+) T-Cells as Immune Tools for Active and Latent Tuberculosis Management. *Front Immunol.* 2018;9:3094. Epub 2019/01/29. doi: 10.3389/fimmu.2018.03094. PubMed PMID: 30687314; PubMed Central PMCID: PMC6334476.
23. Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, Vinhaes CL, Oliveira-De-Souza D, et al. Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection. *Clin Infect Dis.* 2020;71(8):1905-11. Epub 2019/10/31. doi: 10.1093/cid/ciz1070. PubMed PMID: 31665254; PubMed Central PMCID: PMC638463092.
24. Xu F, Zhang H, Si X, Chen J, Chen Y, Cui X, et al. Assessment of CD27 expression on T-cells as a diagnostic and therapeutic tool for patients with smear-negative pulmonary tuberculosis. *Bmc Immunol.* 2021;22(1):41. Epub 2021/06/29. doi: 10.1186/s12865-021-00430-y. PubMed PMID: 34176483; PubMed Central PMCID: PMC8237462.
25. Arpagaus A, Weisser M. [CME: Extrapulmonary Tuberculosis]. *Praxis (Bern 1994).* 2019;108(15):1019-26. Epub 2019/11/28. doi: 10.1024/1661-8157/a003370. PubMed PMID: 31771497.
26. Krishna V, Gopalakrishnan R, Tarigopula A, Panchatcharam SN, Dorairajan SK, Venkatasubramanian R. Utility of Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary tuberculosis. *Indian J Med Microbiol.* 2019;37(3):448-9. Epub 2020/02/01. doi: 10.4103/ijmm.IJMM_19_149. PubMed PMID: 32003351.
27. Stelianides S, Belmatoug N, Fantin B. [Manifestations and diagnosis of extrapulmonary tuberculosis]. *Rev Mal Respir.* 1997;14 Suppl 5:S72-87. Epub 1998/03/13. PubMed PMID: 9496593.
28. Eurosurveillance editorial t. WHO revised definitions and reporting framework for tuberculosis. *Euro Surveill.* 2013;18(16):20455. Epub 2013/04/25. PubMed PMID: 23611033. PubMed PMID: 23611033.
29. WHO. Latent tuberculosis infection updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. 2018. PubMed PMID: 30277688

Figures





Figure 1

Participant enrollment flowchart. TB: tuberculosis; ATB: active tuberculosis; LTBI: latent tuberculosis infection; NTM: non-tuberculous mycobacterium pulmonary disease; OD: other respiratory diseases; HC: healthy control; PTB: pulmonary tuberculosis; EPTB: extra-pulmonary tuberculosis; IGRA: interferon- γ release assay.

A Negative Control



B CD4+IFN- γ + T cells




Figure 2

Flow cytometry gating strategy for CD4⁺IFN- γ ⁺CD38⁺CD27⁻ T cells from the peripheral blood lymphocyte of the participants. (A) Peripheral blood lymphocyte without stimulation by ESAT-6/CFP-10 peptides (negative control) and with 16-h stimulation by ESAT-6/CFP-10 peptides (E6C10). (B) The comparison of CD27 or CD38 expression in ESAT-6/CFP-10 peptides stimulated CD4⁺IFN- γ ⁺ T cells to the unstimulated cells.




Figure 3

The phenotypic markers on CD4⁺ IFN-γ⁺ T cells and on CD4⁺ T cells in peripheral blood of different groups. The phenotypic markers (A) CD4⁺IFN-γ⁺CD27⁺ and CD4⁺IFN-γ⁺CD27⁻; (B) CD4⁺IFN-γ⁺CD38⁺ and CD4⁺IFN-γ⁺CD38⁻; (C) CD4⁺IFN-γ⁺CD38⁺CD27⁻ and CD4⁺IFN-γ⁺CD27⁺CD38⁻; (D)CD4⁺IFN-γ⁺CD27⁺; (E) CD4⁺IFN-γ⁺CD38⁺; and (F) CD4⁺IFN-γ⁺CD38⁺CD27⁻ on CD4⁺ IFN-γ⁺ T cell in peripheral blood stimulated with ESAT 6/CFP10 were compared in ATB and other groups. The phenotypic markers (G) CD4⁺IFN-γ⁺CD27⁺; (H) CD4⁺IFN-γ⁺CD38⁺; and (I) CD4⁺IFN-γ⁺CD38⁺CD27⁻ on CD4⁺ T cell in peripheral blood stimulated with ESAT 6/CFP10 in each group was compared. ATB: active tuberculosis; LTBI: latent tuberculosis infection; NTM: non-tuberculous mycobacterium pulmonary disease; OD: other respiratory diseases; HC: healthy control.




Figure 4

Receiver operating characteristics (ROC) curves and accuracy for the diagnosis of active tuberculosis (ATB). (A) ROC curves of different indicators for the diagnosis of ATB. (B) Sensitivity and specificity corresponding to the cutoff values. The dotted line indicates 80% sensitivity and 80% specificity. (C) The dotted line represents the cutoff value of CD4⁺IFN- γ ⁺CD38⁺CD27⁺/CD4⁺ as 1.34×10^{-4} . ATB: active tuberculosis; LTBI: latent tuberculosis infection; NTM: non-tuberculous mycobacterium pulmonary disease; OD: other respiratory diseases; HC: Healthy control.




Figure 5

The phenotypic marker CD4⁺IFN-γ⁺CD38⁺CD27⁻ on CD4⁺ cells in different subgroups. (A) The phenotypic marker CD4⁺IFN-γ⁺CD38⁺CD27⁻ on CD4⁺ cells with negative TB culture stimulated with ESAT 6/CFP10. (B) The phenotypic marker CD4⁺IFN-γ⁺CD38⁺CD27⁻ on CD4⁺ cells with EPTB stimulated with ESAT 6/CFP10. C⁺: TB culture⁺; C⁻: TB culture⁻; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis; LTBI: latent tuberculosis infection; NTM: non-tuberculous mycobacterium pulmonary disease; OD: other respiratory diseases; HC: healthy control.